1 Comprehensive analyses reveal the impacts of vaccination status and physiological variables in early infection on viral persistence in 2 COVID-19 patients: a retrospective single-center cohort study 3 Xiangxiang Tian^{1,2,3,†}, Yifan Zhang^{1,2,3,†}, Wanhai Wang³, Fang Fang⁴, 4 Wenhong Zhang^{2,5}, Yanmin Wan^{2,5,6,*}, Zhaogin Zhu^{1,*} 5 6 ¹ Department of Laboratory Medicine, Shanghai Public Health Clinical Center, 7 Fudan University, Shanghai, China; ² Department of Infectious Diseases, 8 Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency 9 Response, National Medical Center for Infectious Diseases, Huashan Hospital, 10 Fudan University, Shanghai, China; ³ Clinical Laboratory, The First Affiliated 11 Hospital of Zhengzhou University, Key Laboratory of Laboratory Medicine of 12 Henan Province, Zhengzhou, China; ⁴ Shanghai Public Health Clinical Center, 13 Fudan University, Shanghai, China; ⁵ Department of radiology, Shanghai 14 Public Health Clinical Center, Fudan University, Shanghai, China; ⁶ State Key 15 16 Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai, China. 17 [†]These authors contribute equally to this work. 18 *Address correspondence to: Y.W., #12 Middle Wulumugi Road, Shanghai 19 20 200040, China; e-mail: yanmin wan@fudan.edu.cn. Z.Z., #2901 Caolang Road, Shanghai 201508, China; e-mail: zhaoqinzhu@163.com. 21 **Keywords:** COVID-19, inactivated vaccine, mRNA vaccine, laboratory 22 variables, viral RNA shedding 23 24 Running head: Host factors can predict SARS-CoV-2 persistence 25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 Abstract

27 **BACKGROUND:** Viral persistence is a crucial factor that influences the

communicability of SARS-CoV-2 infection. However, the impacts of

29 vaccination status and physiological variables on viral RNA shedding have not

30 been adequately clarified.

31 **METHODS:** In this study, we retrospectively collected the clinical records of

32 377 hospitalized COVID-19 patients, which contained unvaccinated patients

33 and patients received two doses of an inactivated vaccine or an mRNA vaccine.

34 Firstly, we analyzed the impacts of vaccination on disease severity and viral

35 RNA persistence. Next, to clarify the impacts of physiological variables on viral

36 RNA shedding in COVID-19 patients, we retrieved 49 laboratory variables and

analyzed their correlations with the duration of viral RNA shedding. Finally, we

38 established a multivariate regression model to predict the duration of viral RNA

39 shedding.

40 **RESULTS:** Our results showed that both inactivated and mRNA vaccines

significantly reduced the rate of moderate cases, while the vaccine related

42 shortening of viral RNA shedding were only observed in moderate patients.

43 Correlation analysis showed that 10 significant laboratory variables were

shared by the unvaccinated mild patients and mild patients inoculated with an

inactivated vaccine, but not by the mild patients inoculated with an mRNA

46 vaccine. Moreover, we demonstrated that a multivariate regression model

47 established based on the variables correlating with viral persistence in

48 unvaccinated mild patients could predict the duration of viral shedding for all49 groups of patients.

CONCLUSIONS: Vaccination contributed limitedly to the clearance viral RNA
 in COVID-19 patients. While, laboratory variables in early infection could
 predict the persistence of viral RNA.

- 53
- 54
- 55

56 Introduction

Real world studies suggest that the implementing of vaccination have 57 dramatically reduced the rates of SARS-CoV-2 infection and SARS-CoV-2 58 related hospitalization, admission to intensive care unit and death (1-3). In 59 addition, retrospective estimations have also suggested that vaccines were 60 effective at preventing the transmission of both the Alpha (4, 5) and the Delta 61 variants (6). It is believed that the vaccine mediated reduction of transmission 62 63 relies on the prevention of infection, while the effect of vaccines in preventing onward transmission after breakthrough infections has not been adequately 64 clarified. 65 It is postulated that vaccines may help to restrain the onward transmission of 66 SARS-CoV-2 (7) based on observations that COVID-19 vaccination can 67 reduce viral loads in nasal mucosa (8-10). However, contradictory evidence 68 showed that the viral loads of breakthrough infections after full vaccination 69 were similar with those in unvaccinated individuals (11, 12). More recently, a 70 71 preprint study carried out in a prison demonstrated that there was no significant difference in the duration of RT-PCR positivity and the kinetics of Ct 72 values between fully vaccinated participants and those not fully vaccinated 73 (13). 74

Given that the duration of virus shedding may have crucial impact on the 75 onward transmission of SARS-CoV-2, in this study, we retrieved the clinical 76 records of 377 hospitalized COVID-19 patients and analyzed the impacts of 77 vaccination status and physiological variables in early infection on the duration 78 79 of viral RNA shedding. Comparisons between fully vaccinated and 80 unvaccinated patients showed that vaccination shortened the duration of viral RNA shedding among moderate COVID-19 patients, while showed no effect in 81 constraining the duration of viral RNA shedding among mild COVID-19 82 patients. Furthermore, we showed that vaccination status impacted the 83 association between individual physiological parameters and the duration of 84 viral RNA shedding. Nonetheless, multivariate regression analyses showed 85

- that variables correlated with viral persistence in unvaccinated mild patients
- could predict the duration of viral RNA shedding for all groups of patients.
- 88

89 Materials and methods

90 Ethics statement

- 91 This study was approved by the Research Ethics Review Committee (Ethics
- 92 Approval Number: YJ-2020-S080-02) of the Shanghai Public Health Clinical
- 93 Center Affiliated to Fudan University.
- 94

95 Study design and participants

377 COVID-19 patients hospitalized in Shanghai Public Health Clinical Center 96 during the period from January 2020 to mid-January 2022 were included in this 97 study. The diagnosis and clinical management of COVID-19 patients were 98 conducted following the Diagnosis and Treatment Protocol for Novel 99 Coronavirus Pneumonia released by National Health Commission & National 100 101 Administration of Traditional Chinese Medicine (14). The demographic and COVID-19 vaccination information was depicted in Table 1. 49 laboratory 102 variables detected at the immediate early stage of infection and the duration of 103 viral RNA shedding were shown in Supplemental table 1. The duration of viral 104 105 RNA shedding was defined as the period from the initial nasal swab RT-PCR positivity to the final nasal swab RT-PCR positivity. Patients with identified 106

- 107 comorbidities were excluded from this study.
- 108

109 SARS-CoV-2 viral RNA detection

110 Viral RNA extraction was performed using an automatic nucleic acid extractor

- (Bioperfectus technologies Co., LTD., Jiangsu, China). 2019-nCoV nucleic
- acid detection kit (Bioperfectus technologies Co., LTD., Jiangsu, China) and
- 113 ABI 7500 real-time fluorescence quantitative PCR (qPCR) instrument (Thermo
- 114 Fisher Technology Co., LTD., Shanghai, China) were used to detected
- 115 SARS-CoV-2 genomic RNA. When the Ct values of both ORFlab and N gene

- of 2019-nCoV are \leq 37 and the amplification curve is "S-shaped", the result is
- defined as positive. When the Ct values of both genes are > 40 or
- undetermined, the result is defined as negative. When the Ct value is between
- 119 37~40, the sample would be re-examined.
- 120

121 Laboratory measurements

All the laboratory tests were carried out following manufacturers` instructions

in the department of laboratory medicine of Shanghai Public Health Clinical

124 Center. All the tests had passed the ISO15189 accreditation. In this study, we

retrospectively retrieved the values of 49 laboratory variables (Supplemental

- table 1) for each patient, which were measured at a median of 3 days postdiagnosis.
- 128

129 Statistical analysis

130 Quantitative data were examined for normality using the Shapiro–Wilk test

131 before all downstream analyses except the Chi square test. Means for

132 variables with a normal distribution were compared using the two-tailed

133 parametric t-test and with the two-tailed non-parametric t-test when

distributions of data departed from normality. Pearson correlation was used for

- 135 correlation analyses of normally distributed data and Spearman correlation
- 136 was used for analyses of non-normally distributed data. Multivariate regression
- analyses were performed for variables with statistical significance by the

138 correlation analysis. $P \le 0.05$ was considered as statistically significant. All the

statistical analyses were conducted using Graphpad Prism 9 (GraphPadSoftware, USA).

141

142 **Results**

143 Vaccines reduced the proportion of the moderate cases and shortened

144 the duration of viral RNA shedding among moderate COVID-19 patients

145 In this study, we retrospectively retrieved the clinical records of 377 COVID-19

patients hospitalized in Shanghai Public Health Clinical Center during the 146 period from January 2020 to mid-January 2022. Among these patients, 165 147 received two doses of an inactivated vaccine, 41 received two doses of an 148 mRNA vaccine and 171 were not vaccinated (W/O vaccination) (Table 1). The 149 median age was similar across all groups (P=0.5651), and the mean 150 time-since-vaccination of patients inoculated with an inactivated vaccine was 151 comparable with that of patients inoculated with an mRNA vaccine (P=0.1183) 152 153 (Table 1). The gender composition of patients inoculated with an mRNA vaccine was significantly different from the other two groups, which contained 154 more female (P = 0.0011) (Table 1), but it did not impact the duration of viral 155 RNA shedding and the severity of disease (Supplemental figure 1). 156 Compared with unvaccinated patients, patients inoculated with either an 157 inactivated vaccine (19.4% vs 35.7%, P=0.0002) or an mRNA vaccine (7.3% 158 vs 35.7%, P=0.0001) significantly reduced the incidence of moderate cases 159 (Figure 1A). More interestingly, we found that patients inoculated with an 160 161 inactivated vaccine showed significantly shorter duration of viral RNA shedding in moderate patients compared with unvaccinated patients (17, IQR 162 12.25-19.5 vs 19, IQR 12-24.5, P=0.0382) and patients inoculated with an 163 mRNA vaccine (17, IQR 12.25-19.5 vs 22.33 ± 4.163, P=0.0385) (Figure 1B). 164 However, the vaccines showed no effect in constraining the duration of viral 165 RNA shedding in mild COVID-19 patients (Figure 1C). 166 167

168 Common variables that correlated with the duration of viral RNA

169 shedding were found in unvaccinated mild patients and mild patients

- inoculated with an inactivated vaccine, but not in those inoculated with
- 171 an mRNA vaccine

As aforementioned, the vaccines failed to constrain the duration of viral RNA shedding in mild COVID-19 patients (Figure 1C), which implies that vaccine induced immune responses might not play a pivotal role in determining viral persistence in these patients. To identify physiological variables that are

relevant to the duration of viral RNA shedding in the mild COVID-19 patients. 176 we performed correlation analyses between the duration of viral RNA shedding 177 and 49 laboratory variables detected at the immediate early stage of infection. 178 Our data showed that 16 variables in unvaccinated patients (Figure 2A) and 15 179 variables in patients inoculated with an inactivated vaccine (Figure 2B) 180 correlated with the duration of viral RNA shedding, respectively. Of note, 10 181 variables were shared by these two groups of mild patients, including 3 182 183 positively correlated variables (Fibrinogen, Monocyte and IL-17) and 7 negatively correlated variables (Neutrophil, Eosinophil, Basophil, CD4, CD8, 184 CD19 and CD16CD56 cell counts). In contrast, in patients inoculated with an 185 mRNA vaccine, only eGFR (estimated glomerular filtering rate) was found to 186 correlate negatively with the duration of viral RNA shedding (Figure 2C). Next, 187 we compared the laboratory variables among the three groups of mild 188 COVID-19 patients and found that inoculations with an inactivated vaccine or 189 an mRNA vaccine influenced the laboratory parameters differentially 190 191 (Supplemental table 1). Patients inoculated with an mRNA vaccine mounted highest median IL-8 and IL-17 responses at the immediate early stage of 192 infection (Supplemental table 1). 193

194

195 Variables correlating with the duration of viral RNA shedding in

196 unvaccinated mild patients could predict the duration of viral RNA

197 shedding in all groups of patients

Although multiple individual parameters were found to correlate significantly 198 199 with the duration of viral RNA shedding, the correlation coefficients were low (|r| < 0.5) (Figure 2), suggesting that the correlations were relatively weak. 200 This notion was supported by the results of univariate logistic regression 201 analyses, which showed that no individual variable could reliably discriminate 202 between short duration of viral RNA shedding (≤14 days) from long shedding 203 duration (>14 days) in unvaccinated mild patients (AUC<0.80) (Supplemental 204 figure 2). The count of CD19⁺ B cell is of the highest discriminating efficiency 205

(AUC=0.7556) followed by the count of CD4⁺ T cell (AUC=0.7261)

(Supplemental figure 2). To further characterize the relationships between host 207 factors and viral persistence, we performed multivariate logistic regression 208 analyses leveraging the significant factors identified in the correlation analyses 209 for unvaccinated mild patients. Our results showed that the selected laboratory 210 variables discriminated between the short (≤14 days) and long (>14 days) viral 211 RNA shedding duration quite well for all the three groups of mild COVID-19 212 213 patients. The area under the ROC curve (AUC) for unvaccinated patients, patients inoculated with an inactivated vaccine and patients inoculated with an 214 mRNA vaccine were 0.9231, 0.8365 and 0.9508, respectively (Figure 215 3). Moreover, we found that this multivariate regression model could also 216 predict the duration of viral RNA shedding in moderate COVID-19 patients. 217 The AUC for unvaccinated moderate patients and moderate patients 218 inoculated with an inactivated vaccine were 0.9110 and 0.9514, respectively 219 (Figure 4). Due the limited sample size (only three patients), the multivariate 220 221 regression analysis could not be applied to moderate patients inoculated with an mRNA vaccine. 222

223

224 Discussion

An important factor that influences the transmission of SARS-CoV-2 is the

226 period of communicability, which may be influenced by many factors. To

identify these factors, detections of live virus and viral RNA are frequently used

as indicators of communicability, of which the live virus culture is thought to be

more relevant to the communicability of SARS-CoV-2 infections (15-17).

However, the culture of live viruses is time-consuming and might be affected

by specimen quality and the sensitivities of laboratory methods. Hence, as an

alternative solution, the measurement of viral RNA shedding remains to be an

important criterion for the diagnosis of COVID-19 and the discharge of

hospitalized patients (18).

235 Multiple factors have been found to associate with prolonged viral RNA

shedding in previous studies, such as old age (19), compromised immune
status (20), treatment with corticosteroids (21-23) and disease severity (24,
25). Meanwhile, biological sex and comorbidities, such as hypertension and
diabetes, were found not to associate with the viral RNA shedding (26-28).
Unlike most previous works, our current study investigated the impacts of
vaccination status and multiple laboratory variables in early infection on the
duration of viral RNA shedding.

243 First of all, we compared the ratios of moderate COVID-19 cases among unvaccinated patients and patients fully vaccinated with either an inactivated 244 vaccine or an mRNA vaccine. Our data showed that both the inactivated and 245 the mRNA vaccines significantly reduced the incidence of moderate cases, 246 which is in consistence with the observation of a previous real-world study (29). 247 Next, we compared the duration of viral RNA shedding between unvaccinated 248 and fully vaccinated patients. Quite unexpectedly, our results showed that 249 vaccination significantly shortened the duration of virus shedding in moderate 250 251 patients but not in mild patients, suggesting that vaccine induced specific immune responses did not contribute significantly to constraining viral 252 persistence in mild patients. We were not able to elaborate the underlying 253 254 mechanism in this retrospective study. However, as previous studies suggested that more severe COVID-19 could usually evoke stronger host 255 immune responses (30, 31), we speculate that the memory immune responses 256 257 established by vaccination could be more efficiently activated in moderate patients, which may control the in vivo virus replication better. 258 259 Next, to characterize host factors that may affect viral persistence in mild COVID-19 patients, we retrieved 49 laboratory variables which were detected 260 at the immediate early stage after infection (at a median of 3 days post 261 diagnosis). Correlation analyses showed that the plasma levels of IL-17, 262 fibrinogen and the counts of peripheral leucocytes were associated with the 263 duration of viral RNA shedding in both unvaccinated patients and patients 264 inoculated with an inactivated vaccine. Elevated levels of proinflammatory 265

cytokines and lymphopenia have been demonstrated to be associated with 266 prolonged viral RNA shedding by previous studies (32-34). Here, we further 267 268 showed that the counts of T, B, NK, neutrophil and eosinophil were negatively associated with the duration of viral RNA shedding, while the count of 269 monocyte was positively associated with the duration of viral RNA shedding. 270 More intriguingly, our data showed that all the significant individual variables 271 identified in unvaccinated patients and patients inoculated with an inactivated 272 273 vaccine were not significantly associated with the duration of viral RNA shedding in patients inoculated with an mRNA vaccine. This phenomenon 274 implies that the mRNA vaccine may have unique impacts on host responses 275 after break through infection. And these impacts might be deleterious, because 276 the median duration of viral RNA shedding of patients inoculated with an 277 mRNA vaccine tended to be longer than those of unvaccinated patients and 278 patients inoculated with an inactivated vaccine. Insight into the underlying 279 mechanisms will help to improve our understanding of the biological effect of 280 281 mRNA vaccine.

At the end of this study, we established a multivariate regression model using the individual factors correlating with the duration of viral RNA shedding in unvaccinated mild patients and found that the model could be applied to all groups of patients, including the mild patients inoculated with an mRNA vaccine and the moderate patients. This finding suggests that despite of the impacts of vaccination status and the difference of disease severity, the combined effect of host factors on viral persistence remains stable.

Several limitations of the present study should be noted. First, antigen-specific immune responses were not detected in this retrospective work. Nonetheless, we speculate that the vaccine induce immunities might not be able to constrain viral RNA shedding in mild COVID-19 patients, since both an inactivated vaccine and an mRNA vaccine failed to shorten the duration of viral RNA shedding in these patients. Second, although a previous study showed that viral RNA load (>10⁷ copies/ml) is an independent risk factor for live virus

shedding (35), the detection viral RNA might not always indicate the presence 296 of live viruses. Further investigations are necessitated to characterize host 297 factors that associate with the shedding of viable viruses. Third, most cases 298 enrolled in this study were infected by either the D614G variant or the Delta 299 variant, but we were not able to define the infected variant for each case. 300 Therefore, the impact of viral factor on the duration of viral RNA shedding is 301 out-of-scope for this study. 302 303 Despite of these limitations, our study showed for the first time that COVID-19 vaccines contributed to the clearance viral RNA in moderate cases, while failed 304 to shorten the duration of viral RNA shedding in mild patients. Moreover, we 305

identified a set of laboratory variables in early infection that could predict the
 persistence of viral RNA. These findings may serve as a rationale to optimize

- the control measures for COVID-19 pandemic.
- 309
- 310 Author contributions: All authors confirmed they have contributed to
- 311 the intellectual content of this paper and have met the following
- 312 4 requirements: (a) significant contributions to the conception and
- 313 design, acquisition of data, or analysis and interpretation of data; (b)
- 314 drafting or revising the article for intellectual content; (c) final approval of the
- 315 published article; and (d) agreement to be accountable for
- 316 all aspects of the article thus ensuring that questions related to the accuracy or
- 317 integrity of any part of the article are appropriately investigated
- 318 and resolved.
- 319 ZZ and YW designed and supervised the study; XT and YZ collected the data;
- 320 YW, XT and YZ analyzed the data; XT and YZ drafted the manuscript; YW, ZZ
- and WZ revised the manuscript. The underlying data have been verified by FF,
- 322 **ZZ** and YW.
- 323

```
324 Authors' Disclosures or Potential Conflicts of Interest: Upon manuscript
```

- 325 submission, all authors completed the author disclosure form.
- 326 Disclosures and/or potential conflicts of interest:
- 327 **Employment or Leadership:** None declared.

- 328 **Consultant or Advisory Role:** None declared.
- 329 Stock Ownership: None declared.
- 330 Honoraria: None declared.
- **Research Funding:** This work was partly supported by a grant from the
- National Natural Science Foundation of China (81971559), a grant from the
- 333 major project of Study on Pathogenesis and Epidemic Prevention Technology
- 334 System (2021YFC2302500) by the Ministry of Science and Technology of
- 335 China and a grant from the Science and Technology Commission of Shanghai
- 336 Municipality (21NL2600100).
- 337 **Expert Testimony:** None declared.
- 338 **Patents:** None declared.
- **Role of Sponsor:** The funding organizations played no role in the design of
- 340 study, choice of enrolled patients, review and interpretation of data,
- 341 preparation of manuscript, or final approval of manuscript.

342

343 Acknowledgments

- We thank Dr. Liqiu Jia and Ms. Jing Wang for their help in retrieving the clinical
 records of the COVID-19 patients.
- 346

347 **References**

- Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world
 studies: a systematic review and meta-analysis. Infect Dis Poverty 2021;10:132.
- Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of
 COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis
 2022:114:252-60.
- 353 3. Hungerford D, Cunliffe NA. Real world effectiveness of covid-19 vaccines.
 354 2021;374:n2034.
- Shah ASV, Gribben C, Bishop J, Hanlon P, Caldwell D, Wood R, et al. Effect of Vaccination
 on Transmission of SARS-CoV-2. N Engl J Med 2021;385:1718-20.
- 5. Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Effect of Vaccination on

358 Household Transmission of SARS-CoV-2 in England. N Engl J Med 2021;385:759-60.

- Eyre DW, Taylor D, Purver M, Chapman D, Fowler T, Pouwels KB, et al. The impact of
 SARS-CoV-2 vaccination on Alpha & Delta variant transmission. Preprint at
 https://www.medrxiv.org/content/10.1101/2021.09.28.21264260v1 (2021).
- 362 7. Vitiello A, Ferrara F, Troiano V, La Porta R. COVID-19 vaccines and decreased
 363 transmission of SARS-CoV-2. Inflammopharmacology 2021;29:1357-60.
- 364 8. Callaway E. Delta coronavirus variant: scientists brace for impact. Nature 2021;595:17-8.
- 365 9. Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L, et al. Initial report of
 366 decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med
 367 2021;27:790-2.
- 10. Levine-Tiefenbrun M, Yelin I, Alapi H, Katz R, Herzel E, Kuint J, et al. Viral loads of
 Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with
 BNT162b2. Nat Med 2021;27:2108-10.
- 11. Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta K-D, et al. Impact of
 Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in
 the UK. Preprint at https://www. medrxiv.org/content/10.1101/2021.08.18.21262237v1
 (2021).
- Riemersma KK, Grogan BE, Kita-Yarbro A, Halfmann PJ, Segaloff HE, Kocharian A, et al.
 Shedding of Infectious SARS-CoV-2 Despite Vaccination. Preprint at https://www.medrxiv.org/content/10.1101/2021.07.31.21261387v2 (2021).
- 378 13. Salvatore PP, Lee CC, Sleweon S, McCormick DW, Nicolae L, Knipe K, et al. Transmission 379 potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta 380 variant in federal prison. July-August 2021. Preprint at а 381 https://www.medrxiv.org/content/10.1101/2021.11.12.21265796v1 (2021).
- 382 14. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7).
 383 Chin Med J 2020;133:1087-95.
- Manzulli V, Scioscia G, Giganti G, Capobianchi MR, Lacedonia D, Pace L, et al. Real Time
 PCR and Culture-Based Virus Isolation Test in Clinically Recovered Patients: Is the Subject
 Still Infectious for SARS-CoV2? J Clin Med 2021;10:309.
- 387 16. Huang CG, Lee KM, Hsiao MJ, Yang SL, Huang PN, Gong YN, et al. Culture-Based Virus

388 Isolation To Evaluate Potential Infectivity of Clinical Specimens Tested for COVID-19. J
389 Clin Microbiol 2020:58:e01068-e20.

- 390 17. Jefferson T, Spencer EA, Brassey J, Heneghan C. Viral Cultures for Coronavirus Disease
 391 2019 Infectivity Assessment: A Systematic Review. Clin Infect Dis 2021;73:e3884-e99.
- 392 18. Jin YH, Zhan QY, Peng ZY, Ren XQ, Yin XT, Cai L, et al. Chemoprophylaxis, diagnosis,
 393 treatments, and discharge management of COVID-19: An evidence-based clinical
 394 practice guideline (updated version). Mil Med Res 2020;7:41.
- 395 19. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and
 396 MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a
 397 systematic review and meta-analysis. Lancet Microbe 2021;2:e13-e22.
- Zhu L, Gong N, Liu B, Lu X, Chen D, Chen S, et al. Coronavirus Disease 2019 Pneumonia
 in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in
 Wuhan, China. Eur Urol 2020;77:748-54.
- 401 21. Hu F, Yin G, Chen Y, Song J, Ye M, Liu J, et al. Corticosteroid, oseltamivir and delayed
 402 admission are independent risk factors for prolonged viral shedding in patients with
 403 Coronavirus Disease 2019. Clin Respir J 2020;14:1067-75.
- Liu W, Liu Y, Xu Z, Jiang T, Kang Y, Zhu G, et al. Clinical characteristics and predictors of
 the duration of SARS-CoV-2 viral shedding in 140 healthcare workers. J Intern Med
 2020;288:725-36.
- 407 23. Qi L, Yang Y, Jiang D, Tu C, Wan L, Chen X, et al. Factors associated with the duration of
 408 viral shedding in adults with COVID-19 outside of Wuhan, China: a retrospective cohort
 409 study. Int J Infect Dis 2020;96:531-7.
- 410 24. Park M, Pawliuk C, Nguyen T, Griffitt A, Dix-Cooper L, Fourik N, et al. Determining the
 411 period of communicability of SARS-CoV-2: A rapid review of the literature. Preprint at
 412 https://www.medrxiv.org/content/10.1101/2020.07.28.20163873v1
- 413 25. Fontana LM, Villamagna AH, Sikka MK, McGregor JC. Understanding viral shedding of
 414 severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literature.
 415 Infect Control Hosp Epidemiol 2021;42:659-68.
- 416 26. Stehlik P, Alcorn K, Jones A, Schlebusch S, Wattiaux A, Henry DA. Repeat testing for
 417 SARS-CoV-2: persistence of viral RNA is common, and clearance is slower in older

- 418 people. Med J Aust 2021;214:468-70.
- 419 27. Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W, et al. Factors Associated With Prolonged Viral
 420 RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19). Clin Infect Dis
 421 2020;71:799-806.
- 422 28. Zhou C, Zhang T, Ren H, Sun S, Yu X, Sheng J, et al. Impact of age on duration of viral
 423 RNA shedding in patients with COVID-19. Aging (Albany NY) 2020;12:22399-404.
- 424 29. Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, et al. Association
 425 Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. Jama
 426 2021;326:2043-54.
- Mariën J, Ceulemans A, Michiels J, Heyndrickx L, Kerkhof K, Foque N, et al. Evaluating
 SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe
 and mild COVID-19 cases using a Luminex bead-based assay. J Virol Methods
 2021;288:114025.
- 431 31. Reynolds CJ, Swadling L, Gibbons JM, Pade C, Jensen MP, Diniz MO, et al. Discordant
 432 neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2
 433 infection. Sci Immunol 2020;5:eabf3698.
- 434 32. Gao C, Zhu L, Jin CC, Tong YX, Xiao AT, Zhang S. Proinflammatory cytokines are
 435 associated with prolonged viral RNA shedding in COVID-19 patients. Clin Immunol
 436 2020;221:108611.
- 437 33. Hao S, Lian J, Lu Y, Jia H, Hu J, Yu G, et al. Decreased B Cells on Admission Associated
 438 With Prolonged Viral RNA Shedding From the Respiratory Tract in Coronavirus Disease
 439 2019: A Case-Control Study. J Infect Dis 2020;222:367-71.
- 440 34. Mondi A, Lorenzini P, Castilletti C, Gagliardini R, Lalle E, Corpolongo A, et al. Risk and
 441 predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a
 442 large cohort of COVID-19 patients admitted to an Italian reference hospital. Int J Infect
 443 Dis 2021;105:532-9.
- van Kampen JJA, van de Vijver D, Fraaij PLA, Haagmans BL, Lamers MM, Okba N, et al.
 Duration and key determinants of infectious virus shedding in hospitalized patients with
 coronavirus disease-2019 (COVID-19). Nat Commun 2021;12:267.

	Inactivated vaccine (N=165)	mRNA vaccine (N=41)	Without vaccination (N=171)	P value
Gender (n)				
Male	126	21	105	0 0011
Female	39	20	66	0.0011
Age, Median (IQR) (Years)	35.0 (25.0-44.0)	30.0 (25.0-46.5)	32.0 (24.0-44.0)	0.5651
Time-since-vaccination				
(Mean±SD) (Days) te: All the vaccinated patients ined as the period from the se	received two doses of ei	ther an inactivated va	- ccine or an mRNA vao OVID-19.	0.1183 ccine. Time-s
(Mean±SD) (Days)	received two doses of ei cond dose of vaccinatior	146.0±63.63 ther an inactivated va to the diagnosis of C	- ccine or an mRNA vao OVID-19.	0.1183 ccine. Time-s
(Mean±SD) (Days)	175.5±90.83 received two doses of ei cond dose of vaccinatior	146.0±63.63 ther an inactivated va to the diagnosis of C	- ccine or an mRNA vao OVID-19.	0.1183
(Mean±SD) (Days)	received two doses of ei	146.0±63.63 ther an inactivated va to the diagnosis of C	- ccine or an mRNA vao OVID-19.	0.1183 ccine. Time-s
(Mean±SD) (Days)	received two doses of ei	146.0±63.63 ther an inactivated va to the diagnosis of C	- ccine or an mRNA vao OVID-19.	0.1183 ccine. Time-s
(Mean±SD) (Days)	received two doses of ei	146.0±63.63 ther an inactivated va to the diagnosis of C	- ccine or an mRNA vao OVID-19.	0.1183 ccine. Time-s

Table 1 Demographical characteristics of COVID-19 patients

469 Figure legends

470 Figure 1 The impacts of vaccination on COVID-19 clinical manifestation

and the duration of viral RNA shedding

- 472 (A) The proportions of mild and moderate COVID-19 cases were compared
- among unvaccinated patients and patients inoculated with an inactivated
- 474 vaccine or an mRNA vaccine. (B) Comparisons of the duration of viral RNA
- shedding among moderate COVID-19 patients. (C) Comparisons of the
- 476 duration of viral RNA shedding among mild COVID-19 patients. Statistical
- analyses were performed by the method of non-parametric t-test.
- 478

479 Figure 2 Correlation analyses between multiple laboratory variables and

the duration of viral RNA shedding in different groups of mild COVID-19 patients

- 482 Data of 49 laboratory variables tested at the immediate early stage of infection
 483 were retrieved and correlations between each individual variable and the
 484 duration of viral RNA shedding were analyzed in unvaccinated mild patients
 485 (A), and mild patients inoculated with either an inactivated vaccine (B) or an
- 486 mRNA vaccine (**C**), respectively. Variables that significantly correlated the
- 487 duration of viral shedding (P < 0.05) were shown in red. Correlation analyses
- 488 were done using Pearson correlation for normally distributed data and
- 489 Spearman correlation for non-normally distributed data. Volcano plots were
- 490 constructed using an online software (http://www.bioinformatics.com.cn).
- 491

492 Figure 3 Variables correlating with viral persistence in unvaccinated mild

⁴⁹³ patients could discriminate between short (≤14 days) and long (>14 days)

494 duration of viral RNA shedding for all mild COVID-19 patients

- 495 Multivariate regression model constructed using significant factors identified in
- 496 unvaccinated mild patients discriminated between short and long duration of
- 497 viral RNA shedding for unvaccinated mild patients (A) and mild patients
- inoculated with an inactivated vaccine (**B**) or an mRNA vaccine (**C**). NPV,

499 negative predictive value; PPV, positive predictive value.

500

- 501 Figure 4 Variables correlating with viral persistence in unvaccinated mild
- ⁵⁰² patients could discriminate between short (≤14 days) and long (>14 days)

503 duration of viral RNA shedding for moderate COVID-19 patients

- 504 Multivariate regression model constructed using significant factors identified in
- ⁵⁰⁵ unvaccinated mild patients discriminated between short and long duration of
- viral RNA shedding for unvaccinated moderate patients (A) and moderate
- 507 patients inoculated with an inactivated patients (**B**).
- 508
- 509

Figure 1 The impacts of vaccination on COVID-19 clinical manifestation and the duration of viral RNA shedding



Figure 2 Correlation analyses between multiple laboratory variables and the duration of viral RNA shedding in different groups of mild COVID-19 patients



Figure 3 Variables correlating with viral persistence in unvaccinated mild patients could discriminate between short (\leq 14 days) and long (>14 days) duration of viral RNA shedding for all mild COVID-19 patients



Figure 4 Variables correlating with viral persistence in unvaccinated mild patients could discriminate between short (≤14 days) and long (>14 days) duration of viral RNA shedding for moderate COVID-19 patients



1.0

It is made available under a CC-BY-NC-ND 4.0 International license .



Supplementary figure 1 The average duration of viral RNA shedding and proportions of mild and moderate COVID-19 cases were similar between male and female patients. (A)The average duration of viral RNA shedding of male patients was similar with that of female patients. (B) The proportions of mild and moderate cases in male patients were comparable with those in female patients.

It is made available under a CC-BY-NC-ND 4.0 International license



Supplementary figure 2 Individual variables could not reliably discriminate between short (\leq 14 days) and long (>14 days) duration of viral RNA shedding for unvaccinated mild COVID-19 patients. Univariate regression analyses showed that each of the significant variables identified in the correlation analyses could not confidently discriminate between short (\leq 14 days) and long (>14 days) duration of viral RNA shedding for the unvaccinated mild COVID-19 patients.

Variables	Normal range	(A)	(B)	(C)	P value P value (A) vs (C) (B) vs (C		P value (A) vs (B)
		Inactivated vaccine (N=133)	mRNA vaccine (N=38)	W/O vaccination (N=110)		P value (B) vs (C)	
Gender (n)							
Male	-	100	20	71	0.0001	0.2461	0.0004
Female	-	33	18	39	0.0901	0.2401	0.0094
Time-since-vaccination		170 7+02 51	140 4+62 42				0 2770
(Days)	-	170.7±92.51	149.4102.42	-	-	-	0.2770
Duration of virus		15 (11 20)	17 5 (12 21)	15 (0 75 23)	0 8236	0 5011	0 6551
shedding (Days)	-	13 (11-20)	17.5 (12-21)	13 (9.75-25)	0.0230	0.5911	0.0001
Sampling timepoint		2 (2 2)	2 (2 1)	2 (2 2)	0.0760	0 1001	0.0670
(Days post diagnosis)	-	3 (2-3)	3 (2-4)	3 (2-3)	0.9709	0.1001	0.0070
Biochemistry							
ALT (U/L)	7-40	18 (13-27)	16 (12-26.75)	17.5 (12-28)	0.6663	0.9068	0.6321
AST (U/L)	13-35	18 (15-23.5)	18.5 (16.75-24)	18 (16-21)	0.5972	0.3879	0.6472
ALP (U/L)	35-100	67 (54.5-81.5)	60.5 (55-70.5)	65 (53-60)	0.5150	0.4316	0.1434
L-γ-GGT (U/L)	7-45	20 (15-35)	20.5 (13-33)	20.5 (14-30.25)	0.5125	0.5942	0.2686
LDH (U/L)	120-250	181 (159-205)	190.6±48.38	177 (157.8-201)	0.4230	0.3417	0.6914
TBil (µmol/L)	3.4-20.5	7.8 (5.65-11.1)	6.5 (4.75-8.15)	7.6 (5.675-10.48)	0.7469	0.0229	0.0098
DBil (µmol/L)	0-8.6	4.1 (3.2-5.7)	3.5 (2.975-4.3)	3.7 (3-4.925)	0.0254	0.4444	0.0155
Alb (g/L)	40-55	45 (43-47)	44.24±2.765	44.89±3.237	0.7724	0.2695	0.1526
GIb (g/L)	20-40	30 (27-33)	29.16±4.290	28.79 [±] 4.182	0.0123	0.6438	0.0962

Supplementary table 1 Comparisons of demographical and laboratory variables among mild COVID-19 patients received the inactivated vaccine, the mRNA vaccine or no vaccine

A/G (%)	1.2-2.4	1.5 (1.375-1.655)	1.546±0.2328	1.591 [±] 0.2536	0.0383	0.3409	0.5021
K (mmol/L)	3.5-5.3	3.875±0.2996	3.961±0.3796	3.9 (3.7-4.125)	0.0758	0.8492	0.1475
Na (mmol/L)	137-147	140.2±1.885	141 (140-142)	139.9 <u>+</u> 1.812	0.1460	0.0042	0.0896
CI (mmol/L)	99-110	104.3±1.946	104.3±1.927	104.7±2.379	0.2555	0.3616	0.8335
Urea (mmol/L)	2.6-7.5	4 (3.3-4.65)	3.766±0.8438	3.98 (3.4-4.605)	0.9671	0.0619	0.0729
SCr (µmol/L)	41-73	76.07 [±] 15.62	70.22±13.58	70.87±13.49	0.0065	0.7999	0.0379
Glu (mmol/L)	3.9-6.1	5.77 (5.14-6.38)	5.565 (5.208-6.218)	5.535 (4.948-6.553)	0.4672	0.5734	0.8831
UA (µmol/L)	150-350	342.8±91.94	313.1±98.38	333.1±86.62	0.4024	0.2392	0.0862
eGFR (mL/ (min*1.73m ²))	>90	104.2±17.67	104.2 (95.29-113.3)	111.1±19.51	0.0044	0.1141	0.4159
Mb(ng/mL)	<25	7.890 (5.325-10.32)	8.620 (6.210-13.25)	8.495 (5.555-11.97)	0.2868	0.6174	0.2159
NT-proBNP (pg/mL)	0-500	69.30 (61.45-181.5)	64.65 (60.83-96.38)	70.51 (60.7-178.9)	0.8380	0.2436	0.1946
CK Isoenzyme (ng/mL)	<5	0.46 (0.3-1.1)	0.7195 <u>+</u> 0.5253	1.21 (0.6-1.82)	<0.0001	0.0002	0.4459
Blood coagulation							
INR	0.8-1.3	0.94 (0.91-0.98)	0.9368±0.0599	0.96 (0.91-1.013)	0.1000	0.0774	0.5193
PTA (%)	75-100	111.5±13.62	109.5 (105-122.5)	108 (96-118.3)	0.0623	0.0803	0.5817
PT(S)	11-14.3	12.6 (12.2-13)	12.52±0.6475	12.8 (12.3-13.43)	0.0348	0.0157	0.3332
APTT(S)	32-43	39.56±4.245	40.38±4.284	40 (37.43-43.30)	0.5022	0.1611	0.2979
FIB (g/L)	2-4	3.097±0.6709	3.31 (2.875-3.95)	2.88 (2.553-3.258)	0.0555	0.0003	0.0134
FDP (µg/mL)	0-5	1.5 (1.13-2.185)	1.295 (0.9975-1.615)	1.620 (0.6425-3.130)	0.7372	0.2508	0.0246
D-D (µg/mL)	0-0.5	0.2000 (0.16-0.295)	0.2100 (0.18-0.235)	0.2200 (0.17-0.2725)	0.6326	0.5744	0.9049
TT (S)	14-21	16 (15.35-16.95)	15.6 (14.68-16)	16.15 (15.5-16.6)	0.7475	0.0003	0.0023
ESR (mm/h)	0-20	7 (4-13)	8.5 (4-19.75)	10 (5-22)	0.0008	0.2571	0.2900
Cytokine							
IL-2 (pg/mL)	<7.5	1.38 (0.27-3.41)	2.19 (0.52-4.118)	0.235 (0-0.9725)	<0.0001	<0.0001	0.1063

IL-8 (pg/mL)	<20.6	12.77 (0-60.27)	55.5 (0-165.5)	0.115 (0-2.01)	<0.0001	<0.0001	0.0286
IL-10 (pg/mL)	<12.9	1.51 (0.42-2.475)	1.135 (0.4475-2.488)	0.78 (0.3125-1.623)	0.0005	0.0627	0.6751
IL-17 (pg/mL)	<21.4	3.52 (1.48-56.29)	57.68 (2.698-71.63)	1.065 (0.1925-2.505)	0.0005	<0.0001	0.0016
Leucocyte count							
N (×10^9/L)	1.8-6.3	3.59 (2.7-4.675)	3.848±1.379	3.828±1.486	0.7770	0.9411	0.7468
E (×10^9/L)	0.02-0.52	0.070 (0.03-0.13)	0.070 (0.02-0.1525)	0.070 (0.02-0.13)	0.6821	0.5316	0.7789
B (×10^9/L)	0-0.06	0.0200 (0.01-0.03)	0.0200 (0.01-0.03)	0.0200 (0.01-0.03)	0.9393	0.5578	0.5792
M (×10^9/L)	0.1-0.6	0.57 (0.435-0.705)	0.525 (0.438-0.745)	0.54 (0.42-0.66)	0.3459	0.3953	0.8106
CD4 (cell/µL)	410-1590	496.5 (365.1-735.5)	582.4±235	600.5 (404.5-824.1)	0.0601	0.4985	0.5421
CD8 (cell/µL)	190-1140	388.4 (239.6-526.1)	381.0 (285.6-492.3)	371.6 (257.4-583.5)	0.4456	0.8143	0.7625
CD19 (cell/µL)	107-698	152.3 (99.97-267.2)	187±92.56	193.7 (111.3-303.9)	0.0218	0.2723	0.5324
CD16CD56 (cell/µL)	95-640	254.0 (166-356)	276.7±158.7	229.0 (145-342.5)	0.2926	0.5310	0.9256
CD4/CD8	0.9-3.6	1.480 (1.12-1.85)	1.350 (1.088-1.633)	1.452 (1.167-1.86)	0.7462	0.2349	0.3016
Arterial blood gas							
рН	7.35-7.45	7.37 (7.34-7.39)	7.36 (7.348-7.38)	7.38 (7.36-7.4)	0.0694	0.0230	0.3442
pCO₂ (KPa)	4.3-6	5.952±0.6798	6.005 (5.718-6.323)	5.685±0.5314	0.0009	0.0005	0.4094
pO₂(KPa)	10-14	13.60 (12.2-14.9)	14.04±2.162	13.45 (12.48-15.03)	0.9175	0.3166	0.2090
SB (mmol/L)	21.3-24.8	24.30 (23.2-25)	24.28 [±] 1.030	24.10 (23.1-24.83)	0.2988	0.1956	0.5894
SpO ₂ (%)	91.9-99	98.10 (97.15-98.75)	98.35 (97.85-98.8)	98.10 (97.4-98.7)	0.4967	0.3560	0.1641
AB (mmol/L)	22-29	25.43±1.825	25.8 (25.03-26.7)	25 (24.08-25.8)	0.0105	0.0036	0.4427

Note: Data conforming to the normal distribution are shown as mean ± standard deviation (SD), and data not conforming to the normal distribution are shown as the median (IQR).

Abbreviations: ALT, glutamic pyruvic transaminase; AST, glutamic oxalo-acetic transaminase; ALP, alkaline phosphatase; L-γ-GGT, gamma glutamyl transferase; LDH, lactate dehydrogenase; TBil, total bilirubin; DBil, Direct Bilirubin; Alb, albumin; globulin; SCr, serum creatinine; Glu, glucose; UA, uric acid; eGFR, estimated glomerular filtering rate; INR, international normalized ratio; PTA, prothrombin activity prothrombin time activity; PT, Prothrombin

time; APTT, activated partial thromboplastin time; FIB, Fibrinogen; FDP, fibrin/fibrinogen degradation products; D-D, D-dimer; TT, thrombin time; Mb, myoglobin; NT-proBNP, N terminal pro B type natriuretic peptide; CK Isoenzyme, creatine kinase isoenzyme; ESR, erythrocyte sedimentation rate; N, neutrophil; E, eosinophil; B, basophil; M, monocyte; SB, standard bicarbonate; AB, actual bicarbonate.